Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,463,466
  • Shares Outstanding, K 77,275
  • Annual Sales, $ 0 K
  • Annual Income, $ -234,330 K
  • EBIT $ -318 M
  • EBITDA $ -316 M
  • 60-Month Beta 1.03
  • Price/Sales 471.02
  • Price/Cash Flow N/A
  • Price/Book 6.09

Options Overview Details

View History
  • Implied Volatility 99.73% (-4.64%)
  • Historical Volatility 29.56%
  • IV Percentile 91%
  • IV Rank 61.59%
  • IV High 139.83% on 04/08/25
  • IV Low 35.42% on 05/21/25
  • Expected Move (DTE 14) 6.80 (15.44%)
  • Put/Call Vol Ratio 1.36
  • Today's Volume 104
  • Volume Avg (30-Day) 1,092
  • Put/Call OI Ratio 1.64
  • Today's Open Interest 22,313
  • Open Int (30-Day) 17,560
  • Expected Range 37.23 to 50.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 9
  • High Estimate -0.99
  • Low Estimate -1.28
  • Prior Year -0.84
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.44 +3.88%
on 12/18/25
46.60 -5.40%
on 12/08/25
+1.20 (+2.81%)
since 12/02/25
3-Month
37.23 +18.41%
on 11/07/25
46.60 -5.40%
on 12/08/25
+4.88 (+12.46%)
since 10/02/25
52-Week
26.74 +64.87%
on 04/09/25
46.60 -5.40%
on 12/08/25
+3.92 (+9.75%)
since 01/02/25

Most Recent Stories

More News
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability...

XENE : 43.95 (-1.94%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 43.95 (-1.94%)
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 43.95 (-1.94%)
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight...

XENE : 43.95 (-1.94%)
Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 43.95 (-1.94%)
Xenon Pharmaceuticals: Q3 Earnings Snapshot

Xenon Pharmaceuticals: Q3 Earnings Snapshot

XENE : 43.95 (-1.94%)
Xenon Reports Third Quarter 2025 Financial Results & Business Update

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to...

XENE : 43.95 (-1.94%)
Xenon to Report Q3 2025 Financial Results on November 3, 2025

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 43.95 (-1.94%)
Xenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization Efforts

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Xenon ( (XENE)...

XENE : 43.95 (-1.94%)
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 43.95 (-1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 48.73
2nd Resistance Point 47.54
1st Resistance Point 46.18
Last Price 43.95
1st Support Level 43.63
2nd Support Level 42.45
3rd Support Level 41.09

See More

52-Week High 46.60
Last Price 43.95
Fibonacci 61.8% 39.01
Fibonacci 50% 36.67
Fibonacci 38.2% 34.33
52-Week Low 26.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar